Skip to main content
Top
Published in: Supportive Care in Cancer 9/2012

01-09-2012 | Short Communication

Emergency department cancer unit and management of oncologic emergencies: experience in Asan Medical Center

Authors: Shin Ahn, Yoon-Seon Lee, Kyung Soo Lim, Jae-Lyun Lee

Published in: Supportive Care in Cancer | Issue 9/2012

Login to get access

Abstract

Purpose

With the increasing incidence of cancer patients, our institute set up an emergency department (ED) unit for cancer (cancer emergency room, CER). We intended to clarify the operating characteristics and administrative benefits of the CER.

Methods

The CER was opened in May 2009. Retrospective review of all patients managed in the CER from January 2010 to December 2010 was performed, and data of the patients during January 2008 to December 2008 were collected to compare the care before and after the introduction of the CER.

Results

A total of 5,502 cancer patients visited the CER during 2010; 88.8 % had solid tumor and 11.2 % had hematologic malignancies. Diagnosis was grouped into four categories: disease progression (55.5 %), infection (22.8 %), treatment-related complications (14.7 %), and noncancer-related problems (7 %). Common treatments included antibiotic administration (28.9 %), pain control (22.9 %), and drainage procedures (16.2 %). Of the 5,502 patients, 52.7 % were discharged, 0.2 % died during the stay, home service was supplied to 0.6 % for palliative care, and 4.5 % were transferred to other hospitals including hospice care center. When compared with the year 2008, inpatient unit admission decreased, cost of care in both ED and inpatient unit was reduced (all P values <0.05). However, length of stay in ED and inpatient unit was not different.

Conclusion

ED unit for cancer has a valuable role in managing patients with cancers, not only progression of disease but also various toxicities related to its treatments.
Appendix
Available only for authorised users
Literature
1.
go back to reference Adelberg DE, Bishop MR (2009) Emergencies related to cancer chemotherapy and hematopoietic stem cell transplantation. Emerg Med Clin North Am 27(2):311–331PubMedCrossRef Adelberg DE, Bishop MR (2009) Emergencies related to cancer chemotherapy and hematopoietic stem cell transplantation. Emerg Med Clin North Am 27(2):311–331PubMedCrossRef
2.
go back to reference Jung KW, Park S, Won YJ, Kong HJ, Lee JY, Park EC, Lee JS (2011) Prediction of cancer incidence and mortality in Korea, 2011. Cancer Res Treat 43(1):12–18PubMedCrossRef Jung KW, Park S, Won YJ, Kong HJ, Lee JY, Park EC, Lee JS (2011) Prediction of cancer incidence and mortality in Korea, 2011. Cancer Res Treat 43(1):12–18PubMedCrossRef
3.
go back to reference Brillman J, Mathers-Dunbar L, Graff L, Joseph T, Leikin JB, Schultz C, Severance HW Jr, Werne C (1995) Management of observation units. American College of Emergency Physicians. Ann Emerg Med 25(6):823–830PubMedCrossRef Brillman J, Mathers-Dunbar L, Graff L, Joseph T, Leikin JB, Schultz C, Severance HW Jr, Werne C (1995) Management of observation units. American College of Emergency Physicians. Ann Emerg Med 25(6):823–830PubMedCrossRef
4.
go back to reference Daly S, Campbell DA, Cameron PA (2003) Short-stay units and observation medicine: a systematic review. Med J Aust 178(11):559–563PubMed Daly S, Campbell DA, Cameron PA (2003) Short-stay units and observation medicine: a systematic review. Med J Aust 178(11):559–563PubMed
5.
go back to reference Martinez E, Reilly BM, Evans AT, Roberts RR (2001) The observation unit: a new interface between inpatient and outpatient care. Am J Med 110(4):274–277PubMedCrossRef Martinez E, Reilly BM, Evans AT, Roberts RR (2001) The observation unit: a new interface between inpatient and outpatient care. Am J Med 110(4):274–277PubMedCrossRef
6.
go back to reference Majem M, Galan M, Perez FJ, Munoz M, Chicote S, Soler G, Navarro M, Martinez-Villacampa M, Garcia del Muro X, Dotor E, Laquente B, Germa JR (2007) The oncology acute toxicity unit (OATU): an outpatient facility for improving the management of chemotherapy toxicity. Clin Transl Oncol 9(12):784–788PubMedCrossRef Majem M, Galan M, Perez FJ, Munoz M, Chicote S, Soler G, Navarro M, Martinez-Villacampa M, Garcia del Muro X, Dotor E, Laquente B, Germa JR (2007) The oncology acute toxicity unit (OATU): an outpatient facility for improving the management of chemotherapy toxicity. Clin Transl Oncol 9(12):784–788PubMedCrossRef
8.
go back to reference Beckett DJ, Raby E, Pal S, Jamdar R, Selby C (2009) Improvement in time to treatment following establishment of a dedicated medical admissions unit. Emerg Med J 26(12):878–880PubMedCrossRef Beckett DJ, Raby E, Pal S, Jamdar R, Selby C (2009) Improvement in time to treatment following establishment of a dedicated medical admissions unit. Emerg Med J 26(12):878–880PubMedCrossRef
10.
go back to reference Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34(6):730–751PubMedCrossRef Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34(6):730–751PubMedCrossRef
Metadata
Title
Emergency department cancer unit and management of oncologic emergencies: experience in Asan Medical Center
Authors
Shin Ahn
Yoon-Seon Lee
Kyung Soo Lim
Jae-Lyun Lee
Publication date
01-09-2012
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 9/2012
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-012-1478-8

Other articles of this Issue 9/2012

Supportive Care in Cancer 9/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine